Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01063322 · ClinicalTrials.gov registry record
New Techniques to Evaluate Mitral Regurgitation
A clinical trial of Mitral Valve Regurgitation, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 50
- Enrollment target
- 2
- Study locations
NCT01063322 is a study of Mitral Valve Regurgitation that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 50 participants, below the 810-participant average among 11 other Mitral Valve Regurgitation trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01063322, a study of Mitral Valve Regurgitation, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: \- Mitral regurgitation, or leaking of the mitral heart valve, is usually studied and assessed with an ultrasound test called a two-dimensional (2D) echocardiogram. While this test has proved very useful, technological improvements have helped researchers develop ways to study the heart valves using imaging with three-dimensional (3D) capabilities. In addition, recently developed magnetic resonance imaging (MRI) techniques may be able to provide better information about the causes and severity of the leak. Researchers are interested in testing these new techniques to determine their usefulness for patients with mitral regurgitation. Objectives: \- To evaluate newer methods of studying mitral regurgitation severity using real-time 3D echocardiography (RT3DE) and cardiac magnetic resonance imaging (CMRI). Eligibility: \- Individuals at least 21 years of age who have been diagnosed with more than mild mitral regurgitation. Design: * Participants will have two procedures as part of this study: an echocardiogram and an MRI scan. * For the echocardiogram, participants will have an ultrasound scan with a special kind of probe. Participants may also receive an injection of a contrast agent to provide a better image of the heart on the scan. The scan will take approximately 1 hour to complete. * For the MRI scan, participants will have a standard MRI with special pads placed on the chest to provide better imaging of the heart. The scan will usually take between 45 and 90 minutes to complete.
Conditions Studied
Study Locations (2)
Maryland
- Suburban Hospital - Bethesda
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-02-01 |
| Est. Completion | 2018-04-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01063322
The ClinicalTrials.gov registry entry for NCT01063322 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 810-participant average among 11 other Mitral Valve Regurgitation trials with a reported enrollment target (94% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mitral Valve Regurgitation appearing as the primary indexed condition, and to 0 interventions.
NCT01063322 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01063322 about?
NCT01063322 is a clinical study titled "New Techniques to Evaluate Mitral Regurgitation". Background: \- Mitral regurgitation, or leaking of the mitral heart valve, is usually studied and assessed with an ultrasound test called a two-dimensional (2D) echocardiogram. While this test has proved very useful, technological improvements have helped researchers develop ways to study the heart...
What is the current status of trial NCT01063322?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2010-02-01. Estimated completion is 2018-04-11.
What conditions does trial NCT01063322 study?
This clinical trial studies the following conditions: Mitral Valve Regurgitation.
Who is sponsoring clinical trial NCT01063322?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01063322 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitral Valve Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)
RECRUITING · NA
-
STS/ACC TVT Registry Mitral Module
RECRUITING
-
AltaValve Pivotal Trial
RECRUITING · NA
-
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
RECRUITING · NA
-
Early Feasibility Study of the Neovasc Tiara™ Mitral Valve System
ACTIVE NOT RECRUITING · NA
-
PARTNER 3 Trial - Mitral Valve in Valve
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.